VCEL
Vericel Corporation
Biotechnology · Healthcare · United States
42.91
close · 2026-10-29
value
21
cheaper than peers21
quality
77
stronger fundamentals77
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 7.75× | 63 |
| price to book | 5.93× | 32 |
| EV to EBITDA | 73.47× | 14 |
| forward P/E | 50.72× | 13 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 7.2% | 83 |
| operating margin | 0.6% | 80 |
| revenue growth | 22.5% | 53 |
| debt to equity | 25.2% | 42 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $55.5M |
| employees | 398 |
| first trade | 1997-02-04 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-04 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.32 | 0.20 | -0.07 | -0.35 |
| free cash flow | $24.7M | -$5.8M | $7.8M | $10.1M |
| net income | $16.5M | $10.4M | -$3.2M | -$16.7M |
| revenue | $276.3M | $237.2M | $197.5M | $164.4M |